KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer

Oncology Reports

Volumn 25, Issue 6, 2011, Pages 1691-1697

  Li, Hong Tao ^a   Lu, Yuan Yuan ^a   An, Yan Xin ^a   Wang, Xin ^a   Zhao, Qing Chuan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

BRAF; KRAS; Metastatic colorectal cancer; Mutation; PIK3CA

Indexed keywords

B RAF KINASE; DNA; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE;

ADULT; AGE; AGED; ARTICLE; CANCER STAGING; CANCER TISSUE; CARCINOGENESIS; CODON; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; EXON; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUTATIONAL ANALYSIS; ONCOGENE; ONCOGENE BRAF; ONCOGENE K RAS; ONCOGENE PIK3CA; POINT MUTATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; SEX DIFFERENCE; SIGNAL TRANSDUCTION;

BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION; NEOPLASM STAGING; PHOSPHATIDYLINOSITOL 3-KINASES; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS;

EID: 79954490871     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1217     Document Type: Article

References (31)

1. Ikenoue T, Kanai F, Hikiba Y, et al: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res 65: 4562-4567, 2005. (Pubitemid 40740791)
2. Cengel KA, Voong KR, Chandrasekaran S, et al: Oncogenic K-Ras signals through epidermal growth factor receptor and wild-type H-Ras to promote radiation survival in pancreatic and colorectal carcinoma cells. Neoplasia 9: 341-348, 2007. (Pubitemid 46608301)
3. Tsareva SA, Moriggl R, Corvinus FM, et al: Signal transducer and activator of transcripton 3 activation promotes invasive growth of colon carcinomas through matrix metalloproteinase inductioa Neoplasia 9: 279-291, 2007.
4. Chiang CT, Way TD, Tsai SJ and Lin JK: Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2 overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. FEBS Lett 581: 5735-5742, 2007.
5. Barault L, Veyries N, Jooste V, et al: Mutations in the RAS-MAPK, PI(3)K (phosphatidylinositol-3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. Int J Cancer 122: 2255-2259, 2008. (Pubitemid 351542328)
6. Yarden Y and Sliwkowski MX: Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2: 127-137, 2001.
7. Scaltriti M and Baselga J: The epidermal growth factor receptor pathway: a model for targeted therapy. Clin Cancer Res 12: 5268-5272, 2006. (Pubitemid 44497237)
8. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J and Bardelli A: Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101: 1308-1324, 2009.
9. Kiaris H and Spandidos DA: Mutations of ras genes in human tumours. Int J Oncol 7: 413-421, 1995.
10. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 67: 2643-2648, 2007. (Pubitemid 46548951)
11. Lievre A, Bachet JB, Le Corre D, et al: KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66: 3992-3995, 2006.
12. Frattini M, Signoroni S, Pilotti S, et al: Phosphatase protein homologue to tensin expression and phosphatidylinositol-3 phosphate kinase mutations in colorectal cancer. Cancer Res 65: 1122-1127, 2005.
13. Freeman DJ, Juan T, Reiner M, et al: Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving Panitumumab alone. Clin Colorectal Cancer 7: 184-190, 2008.
14. Jemal A, Clegg LX, Ward E, et al: Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 101: 3-27, 2004.
15. Sartore-Bianchi A, Martini M, Molinari F, et al: PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targetd monoclonal antibodies. Cancer Res 69: 1851-1857, 2009.
16. Van Cutsem E, Kohne CH, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl Med 360: 1408-1417, 2009.
17. Tol J, Dijkstra JR, Klomp M, et al: Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Eur J Cancer 46: 1997-2009, 2010.
18. Qiu LX, Mao C, Zhang J, et al: Predictive and prognostic value of KRAS mutations in metastatic colorectal cancer patients treated with cetuximab: a meta-analysis of 22 studies. Eur J Cancer 46: 2781-2787, 2010.
19. Allegra CJ, Jessup JM, Somerfield MR, et al: American Society of Clinical Oncology provisional clinical opinion: testirg for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27: 2091-2096, 2009.
20. De Roock W, Claes B, Bernasconi D, et al: Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of Cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762, 2010.
21. Samuels Y, Wang Z, Bardelli A, et al: High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554-561, 2004
22. Chiang JM: Role of K-ras mutations in colorectal carcinoma. Cancer Lett 126: 179-185, 1998.
23. Miyaki M, Iijima T, Yamaguchi T, et al: Mutations of the PIK3CA gene in hereditary colorectal cancers. Int J Cancer 121: 1627-1630, 2007. (Pubitemid 47328725)
24. Glarakis IS, Sawa S and Spandidos DA: Activation of the ras genes in malignant and premalignant colorectal tumors. Oncol Rep 5: 1451-1454, 1998. (Pubitemid 28474093)
25. Ogino S, Kawasaki T, Brahmandam M, et al: Sensitive sequencing method for KRAS mutation detection by Pyrosequencirg. J Mol Diagn 7: 413-421, 2005. (Pubitemid 41149657)
26. Velho S, Oliveira C, Ferreira A, et al: The prevalence of PIK3CA mutations ingastric and colon cancer. Eur J Cancer 41: 1649-1654, 2005. (Pubitemid 40981849)
27. Kato S, Iida S, Higuchi T, et al: PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. Int J Cancer 121: 1771-1778, 2007. (Pubitemid 47417296)
28. Benvenuti S, Frattini M, Arena S, et al: PIK3CA cancer mutations display gender and tissue specificity patterns. Hum Mutat 29: 284-288, 2008. (Pubitemid 351240601)
29. Tol J, Nagtegaal ID and Punt CJ: BRAF mutation in metastatic colorectal cancer. N Engl J Med 361: 98-99, 2009.
30. Richman SD, Seymour MT, Chambers P, et al: KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27: 5931-5937, 2009.
31. Ogino S, Nosho K, Kirkner GJ, et al: PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol 27: 1477-1484, 2009.